Results 151 to 160 of about 77,493 (312)

Dupilumab's Real‐World Efficacy and Safety Across Age Groups for Children and Adolescents With Paediatric Atopic Dermatitis

open access: yesAustralasian Journal of Dermatology, EarlyView.
ABSTRACT Background/Objectives Dupilumab is an anti‐interleukin (IL)‐4 receptor (IL‐4Rα) monoclonal antibody used to manage atopic dermatitis (AD). There is a paucity of real‐world Australian data for dupilumab in paediatric AD, especially regarding differences in clinical profiles between age groups.
Paul Sun Woo Kim   +7 more
wiley   +1 more source

Alopecia Areata Prevalence in Australia: Insights From a Nationally Representative Cross‐Sectional Survey Study

open access: yesAustralasian Journal of Dermatology, EarlyView.
ABSTRACT Background/Objectives To estimate the lifetime and point prevalence of alopecia areata (AA) among Australians aged ≥ 15 years. Methods A cross‐sectional survey was conducted from August to September 2024 in a quota‐balanced sample of the Australian population, aged ≥ 12 years (exploratory objective included participants aged 12–14 years ...
Rodney Sinclair   +9 more
wiley   +1 more source

Establishing the financial burden of alopecia areata and its predictors

open access: yesSkin Health and Disease
Background Alopecia areata (AA) can have a significant impact on wellbeing. Consequently, individuals with AA often seek treatments or products to promote hair regrowth or camouflage their hair loss that incur a financial cost to the individual ...
Fabio Zucchelli   +3 more
doaj   +1 more source

Effect of Anti‐IL‐23 and Anti‐IL‐17 Therapy on Darier Disease: A Case Series

open access: yesAustralasian Journal of Dermatology, EarlyView.
ABSTRACT Darier disease is a rare ATP2A2‐related genodermatosis for which therapeutic options remain limited, as acitretin is often constrained by toxicity and teratogenicity. In this retrospective real‐world case series of eight patients, anti‐IL‐17 therapy showed a more consistent early signal of clinical benefit than anti‐IL‐23 therapy, with greater
Maione Vincenzo   +6 more
wiley   +1 more source

Isoniazid and alopecia

open access: yesLung India, 2011
Somsri Wiwanitkit, Viroj Wiwanitkit
openaire   +3 more sources

Making Teledermatology Services Work: A Realist Review of Success Factors

open access: yesAustralasian Journal of Dermatology, EarlyView.
ABSTRACT The implementation of teledermatology, as with other telehealth services, varies across settings. The aim of this study was to use a modified realist review methodology to synthesise factors that lead to successfully implementing and running teledermatology services.
Monica L. Taylor   +6 more
wiley   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

open access: yesAllergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter   +20 more
wiley   +1 more source

Non‐Invasive Scalp Tape‐Strip RNA Sequencing Captures Disease Activity and Treatment‐Response Signatures in Alopecia Areata

open access: yesAllergy, EarlyView.
Non‐invasive scalp tape‐strip RNA sequencing captures core immune and follicular molecular signatures in alopecia areata. Tape‐strip transcriptomic profiles reflect disease severity and treatment response to baricitinib, with concordance to scalp biopsy‐derived signatures.
Carmen Mochón‐Jiménez   +10 more
wiley   +1 more source

Limited Clinical Impact of Androgen Receptor Repeat Length (CAG and GGC) in Klinefelter Syndrome: A Multivariable Analysis

open access: yesAndrology, EarlyView.
ABSTRACT Background Klinefelter syndrome (KS) is characterized by marked phenotypic heterogeneity that might be influenced by genetic modifiers, including androgen receptor (AR) repeat length (CAGn and GGCn). The clinical relevance of these repeat lengths in patients with KS before testosterone replacement therapy (TRT) remains unclear.
Andrea Graziani   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy